SEC Tracker
Get the app

Insulet PODD

Insulet reports $141.1 million net income for Q3 2026

Form
10-Q
Filed
Importance
Notable
  1. Revenue of $842 million for the three months ended Sep 30, 2026
  2. Diluted EPS of $2.03 for the three months ended Sep 30, 2026
  3. Cash and equivalents of $584.4 million at Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Insulet files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

From the filing's financial data, not stated in its text

From this 10-Q's financial data (XBRL) for the quarter ended September 30, 2026

  • For the quarter ended September 30, 2026, INSULET CORP reported: Revenue $842.0 million.
  • Net income $141.1 million.
  • Gross margin 75.1%.
  • Operating margin 22.5%.
  • Net margin 16.8%.
  • Revenue change from a year earlier +19.2%.

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. MiniMed Group MMED
  2. STERIS STE public float $24.2B, Sep 30, 2025
  3. Zimmer Biomet Holdings ZBH public float $18.0B, Jun 30, 2025
  4. Baxter International BAX public float $16.0B, Jun 30, 2025
  5. West Pharmaceutical Services WST public float $15.7B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.